<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00724048</url>
  </required_header>
  <id_info>
    <org_study_id>ACR16 C009</org_study_id>
    <nct_id>NCT00724048</nct_id>
  </id_info>
  <brief_title>A Study of Pridopidine (ACR16) for the Treatment of Patients With Huntington's Disease</brief_title>
  <acronym>HART</acronym>
  <official_title>A Multi-center, North American, Randomized, Double-blind, Parallel Group Study Comparing Three Doses of ACR16 Versus Placebo for the Symptomatic Treatment of Huntington Disease (HART)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Branded Pharmaceutical Products R&amp;D, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Branded Pharmaceutical Products R&amp;D, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if ACR16 is effective and safe in the symptomatic&#xD;
      treatment of Huntington's Disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sum score of items 4-10 and 13-15 of the UHDRS motor assessment</measure>
    <time_frame>26 Weeks</time_frame>
    <description>The primary objective is to assess the effects of ACR16 on voluntary motor function in HD patients, as defined as the sum score of items 4-10 and 13-15 of the UHDRS motor assessment (a modified motor score in MS) at 26 weeks of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impressions (CGI)</measure>
    <time_frame>At 4, 8, 12 and 26 weeks</time_frame>
    <description>The effects of ACR16 on CGI, cognitive function, behaviour and symptoms of depression and anxiety. CGI has two components-the CGI-Severity, which rates illness severity, and the CGI-Improvement, which rates change from the initiation (baseline) of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event profile</measure>
    <time_frame>30 weeks</time_frame>
    <description>Safety and tolerability assessed from adverse event profile</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">227</enrollment>
  <condition>Huntington Disease</condition>
  <arm_group>
    <arm_group_label>ACR16 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive one ACR16 10mg twice daily:&#xD;
First four weeks - ACR16 10mg qd - one active 10mg capsule daily. After four weeks - ACR16 10mg bid - two active 10mg capsules taken as two separate doses (20mg ACR16 per day).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACR16 22.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive one ACR16 22.5mg capsule twice daily:&#xD;
First four weeks - ACR16 22.5mg qd - one active 22.5mg capsule daily. After four weeks - ACR16 22.5mg bid - two active 22.5mg capsules taken as two separate doses (45mg ACR16 per day).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACR16 45 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive one ACR16 45mg capsule twice daily:&#xD;
First four weeks - ACR16 45mg qd - one active 45mg capsule daily. After four weeks - ACR16 45mg bid - two active 45mg capsule taken as two separate doses (90mg ACR16 per day).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Weeks 1-4, Participants receive a one placebo capsule once daily for four weeks.&#xD;
Weeks 5-26, Participants receive a one placebo capsule taken twice daily as two separate doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACR16 10 mg</intervention_name>
    <description>ACR16 capsules: 10mg twice daily</description>
    <arm_group_label>ACR16 10 mg</arm_group_label>
    <other_name>pridopidine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACR16 22.5 mg</intervention_name>
    <description>ACR16 capsules: 22.5mg twice daily</description>
    <arm_group_label>ACR16 22.5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACR16 45 mg</intervention_name>
    <description>ACR16 capsules: 45mg twice daily</description>
    <arm_group_label>ACR16 45 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able to provide written Informed Consent prior to any study related procedure,&#xD;
             including consent to genotyping of the CYP2D6 gene.&#xD;
&#xD;
          -  Clinical features of HD, and a positive family history and/or the presence of ≥ 36 CAG&#xD;
             repeats in the Huntington gene.&#xD;
&#xD;
          -  Male or female age ≥ 30 years.&#xD;
&#xD;
          -  Willing and able to take oral medication and to comply with the study specific&#xD;
             procedures.&#xD;
&#xD;
          -  Ambulatory, being able to travel to the assessment center, and judged by the&#xD;
             Investigator as likely to be able to continue to travel for the duration of the study.&#xD;
&#xD;
          -  Availability of a caregiver or family member to accompany the subject to two visits.&#xD;
&#xD;
          -  A sum of ≥ 10 points on the mMS at the screening visit.&#xD;
&#xD;
          -  For subjects taking allowed antidepressants or other psychotropic medication , the&#xD;
             dosing of medication must have been kept constant for at least 6 weeks before&#xD;
             enrollment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with any antipsychotic medication (neuroleptics) within 8 weeks of&#xD;
             enrollment, or at any time point during the study period.&#xD;
&#xD;
          -  Use of tetrabenazine within 12 weeks of enrollment, or at any time during the study&#xD;
             period.&#xD;
&#xD;
          -  Treatment with any investigational product within 4 weeks of enrollment.&#xD;
&#xD;
          -  Use of tricyclic antidepressants or class I antiarrhythmics within 6 weeks of&#xD;
             enrollment, or at any time during the study period.&#xD;
&#xD;
          -  Use of concomitant medication that may lower the seizure threshold within 6 weeks of&#xD;
             enrollment, or at any time during the study period .&#xD;
&#xD;
          -  Use of metoclopramide within 12 weeks of enrollment, or at any time during the study&#xD;
             period.&#xD;
&#xD;
          -  Subjects currently receiving deep brain stimulation (DBS).&#xD;
&#xD;
          -  Subjects with a history of surgical procedures aiming to improve the symptoms of&#xD;
             Huntington disease, such as neural transplantations, lesions of the central nervous&#xD;
             system, infusions of neurotrophic agents or previous attempts of deep brain&#xD;
             stimulation.&#xD;
&#xD;
          -  Subjects previously randomized into this study.&#xD;
&#xD;
          -  A prolonged QTc interval at Screening Visit (defined as a QTc interval of &gt; 450 msec&#xD;
             for males or &gt; 470 msec for females), or other clinically significant heart conditions&#xD;
             as judged by the investigator.&#xD;
&#xD;
          -  Creatinine clearance &lt;40mL/min as measured at the screening visit.&#xD;
&#xD;
          -  Any clinically significant, abnormal, baseline laboratory result which in the opinion&#xD;
             of the Investigator, affects the subjects' suitability for the study or puts the&#xD;
             subject at risk if he/she enters the study.&#xD;
&#xD;
          -  Clinically significant hepatic or renal impairment.&#xD;
&#xD;
          -  Subjects with a known history of epilepsy or a history of febrile seizure(s) or&#xD;
             seizure(s) of unknown cause.&#xD;
&#xD;
          -  Severe intercurrent illness, which, in the opinion of the Investigator, may put the&#xD;
             subject at risk when participating in the trial or may influence the results of the&#xD;
             trial or affect the subjects' ability to take part in the trial.&#xD;
&#xD;
          -  Alcohol and/or drug abuse as defined by DSM IV-TR criteria for Substance Abuse - this&#xD;
             includes the illicit use of cannabis within the last 12 months prior to Screening&#xD;
             Visit&#xD;
&#xD;
          -  Subjects with suicidal ideation as defined as a positive score on criteria for major&#xD;
             depressive episode, item A9 on the DSM -IV-TR criteria for a Major Depressive Episode&#xD;
&#xD;
          -  Females who are pregnant or lactating or who intend to become pregnant during the&#xD;
             study period.&#xD;
&#xD;
          -  Females who are of child bearing potential and not taking adequate contraceptive&#xD;
             precautions are excluded from the trial. (Females of child bearing potential taking&#xD;
             acceptable contraceptive precautions can be included)&#xD;
&#xD;
          -  Known allergy to any ingredients of the trial medication or placebo&#xD;
&#xD;
          -  Any previous participation in a clinical study with ACR16.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joakim Tedroff, MD</last_name>
    <role>Study Director</role>
    <affiliation>NeuroSearch A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Neurological Institute</name>
      <address>
        <city>Littleton</city>
        <state>Colorado</state>
        <zip>80120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287-7281</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Charlestown</city>
        <state>Massachusetts</state>
        <zip>02129</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Struthers Parkinson's Center</name>
      <address>
        <city>St. Louis Park</city>
        <state>Minnesota</state>
        <zip>55426</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical College</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore-LIJ Health System</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Parkinson's Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tennessee Health Science Center</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38163</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-9036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Booth Gardner Parkinson's Care Center</name>
      <address>
        <city>Kirkland</city>
        <state>Washington</state>
        <zip>98034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta Glenrose Rehab Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5G 0B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6T 2B5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Centre for Addiction and Mental Health</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L6B1C9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parkinsons and Neurodegenerative Disordes Clinic</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1G4G3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hotel-Dieu Hospital-CHUM</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>July 24, 2008</study_first_submitted>
  <study_first_submitted_qc>July 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2008</study_first_posted>
  <disposition_first_submitted>February 19, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>March 28, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 4, 2013</disposition_first_posted>
  <last_update_submitted>July 20, 2016</last_update_submitted>
  <last_update_submitted_qc>July 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Huntington Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Huntington Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

